Status:
COMPLETED
Inflammatory Markers in Exhaled Breath (Condensate) in Childhood Asthma
Lead Sponsor:
Maastricht University Medical Center
Collaborating Sponsors:
AstraZeneca
Conditions:
Asthma
Healthy
Eligibility:
All Genders
5-18 years
Brief Summary
Background: Exhaled nitric oxide and inflammatory biomarkers in exhaled breath condensate may be useful to diagnose and monitor childhood asthma. Their ability to indicate an asthma diagnosis, and to...
Eligibility Criteria
Inclusion
- Asthmatic and control children, aged 5 to 16 years
- Children with doctor-diagnosed asthma, known at the department of Paediatric Pulmonology, University Hospital Maastricht
Exclusion
- Presence of a disease that might interfere with the results of this study (e.g. recent upper airway infection, heart disease, anatomic abnormalities of the airways and other chronic inflammatory diseases such as Crohns disease and rheumatoid arthritis)
- Mental retardation
- Inability to perform the EBC procedure properly
- Active smoking
- The use of one of the following medication: Papaverin, Sodium nitroprusside, ACE inhibitors, Oxymetazoline, L-arginine, or NOS inhibitors
Key Trial Info
Start Date :
June 1 2004
Trial Type :
OBSERVATIONAL
End Date :
April 1 2005
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT00404976
Start Date
June 1 2004
End Date
April 1 2005
Last Update
November 29 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Maastricht
Maastricht, Netherlands, 6202AZ